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ABSTRACT 
Background: End-stage liver disease (ESLD) is an important cause of morbidity among 
HIV/hepatitis C virus (HCV)-coinfected patients. Quantifying the risk of this outcome over time 
could help determine which coinfected patients should be targeted for risk factor modification 
and HCV treatment. We evaluated demographic, clinical, and laboratory variables to predict risk 
of ESLD in HIV/HCV-coinfected patients receiving antiretroviral therapy (ART). 
 
Methods: We conducted a retrospective cohort study among 6,016 HIV/HCV-coinfected 
patients who received ART within the Veterans Health Administration between 1997 and 2010. 
The main outcome was incident ESLD, defined by hepatic decompensation, hepatocellular 
carcinoma, or liver-related death. Cox regression was used to develop prognostic models based 
on baseline demographic, clinical, and laboratory variables, including FIB-4 and aspartate 
aminotransferase-to-platelet ratio index, previously validated markers of hepatic fibrosis. Model 
performance was assessed by discrimination and decision curve analysis. 
 
Results: Among 6,016 HIV/HCV patients, 532 (8.8%) developed ESLD over a median of 6.6 
years. A model comprising FIB-4 and race had modest discrimination for ESLD (c-statistic, 
0.73) and higher net benefit than alternative strategies of treating no or all coinfected patients at 
relevant risk thresholds. For FIB-4 >3.25, ESLD risk ranged from 7.9% at 1 year to 26.0% at 5 
years among non-blacks and from 2.4% at 1 year to 14.0% at 5 years among blacks. 
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Conclusions: Race and FIB-4 provided important predictive information on ESLD risk among 
HIV/HCV patients. Estimating risk of ESLD using these variables could help direct HCV 
treatment decisions among HIV/HCV-coinfected patients. 
 
 
INTRODUCTION 
Chronic hepatitis C virus (HCV) coinfection is common among patients with HIV 
infection [1]. Liver fibrosis progression is accelerated in HIV/HCV-coinfected patients [2], and 
rates of hepatic decompensation are higher among coinfected than HCV-monoinfected patients, 
even if HIV RNA is fully suppressed on antiretroviral therapy (ART) [3], Consequently, end-
stage liver disease (ESLD) has emerged as an important cause of morbidity in this population [3-
5]. 
Despite the clinical impact of HCV-related ESLD in coinfected patients, no models have 
been developed using readily available demographic, clinical, and laboratory characteristics to 
predict the risk of ESLD within a specified time period. Quantifying ESLD risk over time could 
prompt clinicians and patients to aggressively address modifiable risk factors for this condition 
(e.g., hazardous alcohol use; uncontrolled diabetes; severe anemia; detectable HIV viremia due to 
ART non-adherence and/or resistance [3]) and identify subgroups of patients who should be 
followed closely for liver complications. Since highly efficacious and well tolerated, but costly, 
all-oral direct-acting antivirals for HCV treatment are now available [6, 7], a prognostic model for 
ESLD in coinfected patients could help prioritize the need for HCV therapy among HIV/HCV 
patients, who have an urgent need for HCV treatment [3]. 
We previously identified important risk factors for hepatic decompensation among 
HIV/HCV patients on ART [3]. In this study, we evaluated and compared alternative models 
 at G
W
U
 on July 14, 2015
http://ofid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
5 
comprised of demographic, clinical, and laboratory variables to determine which combination of 
predictors can best classify HIV/HCV patients according to their risk of progression to ESLD 
over time. Since liver fibrosis stage is an important factor used to determine the urgency and 
timing of HCV therapy [8], we first evaluated the prognostic ability of two non-invasive markers 
of hepatic fibrosis (FIB-4; aspartate aminotransferase-to-platelet ratio index [APRI]) that can be 
calculated from routinely measured laboratory data (i.e., liver aminotransferases, platelet count). 
We then evaluated whether the addition of clinical and demographic variables improved the 
predictive ability of these indices. 
 
METHODS 
Study Design and Data Source 
We conducted a retrospective cohort study among ART-treated HIV/HCV-coinfected 
patients in the Veterans Aging Cohort Study (VACS) between January 1, 1997 and September 
30, 2010 [9]. VACS consists of electronic medical record data from HIV-infected patients 
receiving care at Veterans Affairs (VA) medical facilities across the United States. Data include 
demographic characteristics, hospital and outpatient diagnoses (recorded using International 
Classification of Diseases, Ninth Revision [ICD-9] codes), procedures, laboratory results, and 
dispensed medications. Clinically confirmed cancer diagnoses are identified using the VA 
Central Cancer Registry. Date of death was ascertained from the VA Vital Status file [10]. The 
underlying cause of death was determined by linkage with the National Death Index (NDI).[11] 
This study was approved by the Institutional Review Boards of the University of Pennsylvania 
and Philadelphia VA Medical Center. 
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Study Patients 
Coinfected patients were included if they had: 1) HIV (identified using a validated 
algorithm [9]), 2) detectable HCV RNA, and 3) were dispensed ART, defined as use of at least 
three antiretrovirals from two different classes [12] for at least 12 months. We included only 
coinfected patients on ART because current guidelines recommend ART in all HIV/HCV 
patients regardless of CD4 count [12]. The majority of Veterans receive their medications from 
VA pharmacies [13, 14], and prior studies have shown the validity of VA dispensing data as a 
surrogate of actual adherence [15-18]. Patients were excluded if prior to start of follow-up 
(defined below) they had ESLD or received interferon-based therapy (since such treatment can 
affect non-invasive markers of hepatic fibrosis and reduces risk of ESLD [19]). 
Follow-up began after 12 months on ART. The 12 months prior to the start of follow-up 
represented the baseline period, during which predictors were ascertained. Follow-up continued 
until study endpoint, death, initiation of HCV therapy, or last visit before September 30, 2010. 
 
Main Study Outcome 
The primary endpoint was ESLD, defined as hepatic decompensation, hepatocellular 
carcinoma, or liver-related death. Hepatic decompensation was determined by one hospital 
discharge ICD-9 diagnosis or two or more outpatient ICD-9 diagnoses of ascites, spontaneous 
bacterial peritonitis, or esophageal variceal hemorrhage (Appendix 1). The requirement of two 
outpatient diagnoses aimed to exclude events that were suspected, but not subsequently 
confirmed, at follow-up visits. We validated this definition in a prior survey, with 91% of events 
confirmed by medical records [20]. Based on the results of the prior validation study [20], we did 
not include ICD-9 diagnoses for hepatic encephalopathy or jaundice, which could indicate 
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decompensation, since these diagnoses were often linked to unrelated conditions (e.g., narcotic 
overuse, stroke recorded as encephalopathy; biliary obstruction, atazanavir-associated 
hyperbilirubinemia recorded as jaundice). The date of decompensation was defined as the 
hospital discharge date (if identified by hospital diagnosis) or initial outpatient diagnosis date (if 
identified by outpatient diagnoses). Hepatocellular carcinoma was determined using the VA 
Central Cancer Registry, which confirms diagnoses by histology, cytology, or consistent 
radiography. Deaths were considered liver-related if the underlying cause of death in the NDI 
was hepatic decompensation, liver cancer, alcoholic liver disease, viral hepatitis, or non-
alcoholic liver disease [3]. The date of ESLD was defined as the initial date of hepatic 
decompensation, hepatocellular carcinoma, or death from liver disease, whichever occurred first.  
 
Data Collection 
Baseline variables evaluated as predictors of ESLD included: FIB-4 (<1.45; 1.45-3.25; 
>3.25), APRI (<1.0; 1.0-2.0; >2.0), age, body mass index (BMI; <18.5; 18.5-24.9; 25.0-30.0; 
>30.0 kg/m2), severe anemia (hemoglobin <10 g/dL), CD4 cell count <200 cells/mm3, HIV RNA 
>400 copies/mL, alcohol dependence/abuse, diabetes mellitus, hepatitis B coinfection, and non-
black race, which have been shown to be risk factors for advanced liver disease in coinfected 
patients [3, 19, 21]. FIB-4 is a measure of liver fibrosis stage that was developed and validated 
compared to liver biopsy in HIV/HCV-coinfected patients [22]. It is calculated from age, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and platelet count: FIB-4=(age 
[years] x AST [U/L])/((platelet count [109/L]) x (ALT [U/L])1/2). FIB-4 <1.45 identifies 
no/minimal fibrosis, while results >3.25 indicate advanced hepatic fibrosis/cirrhosis.[22] APRI, 
another noninvasive measure of hepatic fibrosis, uses AST and platelet count: APRI=([AST 
 at G
W
U
 on July 14, 2015
http://ofid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
8 
[U/L]/upper limit of normal [considered as 40 U/L])/platelet count (109/L)] x 100.[23] APRI 
>2.0 identifies cirrhosis in chronic HCV, and APRI <0.5 identifies no or minimal fibrosis [23]. 
We collected ALT, AST, platelet count, body weight, hemoglobin, CD4 count, and HIV RNA 
results measured closest to, but prior to, the start of follow-up. Alcohol dependence/abuse was 
defined by previously validated ICD-9 diagnoses (Appendix 1) [24]. Diabetes was defined by 
random glucose 200 mg/dL, ICD-9 diagnosis, and/or anti-diabetic medication use [25]. 
Hepatitis B coinfection was defined by a positive hepatitis B surface antigen. Additional 
variables collected at baseline for descriptive purposes included sex, HCV genotype, and HCV 
RNA. 
 
Statistical Analysis 
We used Cox regression to estimate the relative hazards of ESLD (with 95% confidence 
intervals) for the predictors of interest [26]. We also evaluated FIB-4, APRI, hemoglobin, CD4 
count, and HIV RNA level as continuous variables. 
Next, since the stage of hepatic fibrosis is a strong determinant of ESLD [3, 19] and an 
important factor in the decision to initiate HCV therapy [8], we initially created separate models 
comprising FIB-4 and APRI alone. We then developed two separate lines of prognostic models 
with FIB-4 and APRI as the base models, respectively. Various combinations of the other 
predictors were added to the base models, including an interaction term for race. Age is a 
component of FIB-4 and so was not included in FIB-4 models.  
Each model’s performance was assessed by statistical significance and discrimination, 
using the concordance statistic (c-statistic) as an index of the model’s ability to separate persons 
who will develop ESLD from those who will not [27]. We favored simpler models with fewer 
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predictors that had appreciably different c-statistics from those of FIB-4 or APRI-based models 
alone. Performance of promising models was further compared by decision curves [28, 29], a 
graphical approach for evaluating and comparing prognostic models that considers the inherent 
trade-offs of false-positive versus false-negative classifications arising out of varying risk 
thresholds. Details appear in Appendix 2. From the final model selected, we plotted Kaplan-Meier 
failure curves. Differences in ESLD by FIB-4 categories were estimated using log-rank tests. 
To ensure that missing data did not affect the validity of our results, in a sensitivity 
analysis, we generated 10 imputed datasets, each with completed data on all predictors [30]. Data 
were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC) and Stata 13.1 (Stata Corporation, 
College Station, TX). 
 
RESULTS 
Patient Characteristics 
Between 1997 and 2010, a total of 6,016 ART-treated HIV/HCV-coinfected patients met 
our inclusion criteria (Figure 1). Absence of HCV RNA assessment was a common reason for 
exclusion (18%), but there were no clinically relevant differences in the characteristics between 
included patients and those excluded due to missing HCV RNA (data not shown).  
The cohort (Table 1) was predominantly male and black, and one-quarter had a history of 
alcohol dependence/abuse. Most patients were infected with HCV genotype 1 and had a high 
baseline HCV RNA level. The patients were followed for a median of 6.6 (interquartile range, 3.4-
9.8) years. During follow-up, 482 (8.0%) patients initiated HCV therapy during follow-up and 
were censored. 
ESLD occurred in 532 (8.8%) patients during follow-up. At the time of the first ESLD 
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event, a diagnosis indicative of hepatic decompensation was recorded in 397 (6.6%), 
hepatocellular carcinoma in 63 (1.0%), and liver-related death in 72 (1.2%). Among the 397 
patients with an incident hepatic decompensation event, 335 (84.4%) had ascites, 71 (17.9%) 
spontaneous bacterial peritonitis, and 110 (27.7%) variceal hemorrhage. Overall, 1,936 (32.2%) 
patients died during follow-up, of which 164 (8.5%) were liver-related deaths (Appendix 3). 
 
Performance and Comparison of Prognostic Models for ESLD 
Baseline FIB-4, baseline APRI, and non-black race were the strongest factors associated 
with ESLD among the variables evaluated in Cox regression analyses (Appendix 4). Interactions 
with race were not observed for FIB-4 or APRI.Discrimination was similar for models with FIB-
4 (c-statistic, 0.70) and APRI (c-statistic, 0.71) alone (Table 2). Alternative models comprising 
FIB-4 and race (c-statistic, 0.73) and APRI, age, and race (c-statistic, 0.74) had higher 
discrimination, but further addition of other combinations of predictors did not result in 
appreciably increased model discrimination (Table 2). Results of the decision curve analysis are 
shown in Appendix 5. Since the model with FIB-4 + race had comparable discriminative ability 
and was simpler than the one with APRI + age + race, the model with FIB-4 + race was selected 
as the final model. 
The risk of ESLD among non-blacks and blacks by category of FIB-4 is shown in Panels 
A and B of Figure 3, respectively (log-rank test among non-blacks, p<0.001; among blacks, 
p<0.001). The risk at 5 years ranged from 2.6% to 26% among non-blacks (Figure 3a) and 2.0% 
to 14.0% among blacks (Figure 3b) across FIB-4 levels.  
Analyses using imputed data produced similar results. 
 
 at G
W
U
 on July 14, 2015
http://ofid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
11 
DISCUSSION 
This study evaluated prognostic models for determining the risk of developing ESLD in 
ART-treated HIV/HCV-coinfected patients. A prognostic model for risk of developing ESLD 
comprising FIB-4 and race had better discriminative accuracy than FIB-4 or APRI alone, and 
was comparable to the APRI, age, and race model, but simpler. Using established cut-points of 
FIB-4, we determined the risk of ESLD over time in non-blacks and blacks. Despite including a 
number of additional variables associated with progression to ESLD (Appendix 3), a model with 
all candidate predictors did not appreciably increase prognostic ability.  
Importantly, our analyses in Figure 2 demonstrated that for HIV/HCV-coinfected 
individuals with moderate fibrosis by FIB-4 (i.e., results ranging from 1.45-3.25), there remains 
a significant risk of ESLD for non-blacks (>16% at 10 years) and blacks (>10% at 10 years). 
These results provide additional evidence that coinfected patients with at least moderate (F2) or 
higher liver fibrosis be strongly considered for HCV treatment and should not be deferred until 
the development of more advanced liver disease, where the risk of ESLD will be even higher. 
With the availability of all-oral direct-acting anti-HCV regimens that have high virologic 
cure rates and tolerability, but which are very costly, determining the rational use of these agents 
is imperative [31]. Quantifying the absolute risk of ESLD over time using a simple prognostic 
model comprising FIB-4 and race could have important clinical implications for the management 
of coinfected patients. Identifying coinfected patients at higher risk of ESLD could help 
prioritize HCV treatment in those who would benefit from it most and inform the need for close 
monitoring for liver-related complications. Alternatively, in those with a low risk of ESLD, 
emphasis could be placed on the modification of other risk factors for ESLD, including the 
reduction of alcohol consumption, control of diabetes, and HIV suppression, as well as clinical 
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monitoring for liver disease progression. Analogous to other quantitative risk assessment tools, 
such as the Framingham Coronary Heart Disease Risk Score [32] and World Health 
Organization Fracture Risk Assessment Tool (FRAX) [33], which estimate the 10-year risk of 
cardiovascular disease and fracture, respectively, use of this ESLD risk model could aid the 
management of chronic HCV in patients with HIV, more than simply knowing which factors are 
predictive of developing ESLD. 
If validated, this model could contribute to an individualized approach to HCV treatment 
among HIV/HCV patients. We sought to develop a simple model that reports ESLD risk over a 
10-year period in both graphical and tabular form to allow easy interpretation by coinfected 
patients and their providers. Since the exact risk of ESLD that should prompt initiation of HCV 
treatment remains unclear, providers could use these results to discuss a patient’s likelihood of 
developing ESLD over time and consider what risk of ESLD, in conjunction with other clinical 
and demographic factors, would prompt their initiation of HCV therapy. 
FIB-4 is clinically credible as a predictor, easy to compute, and could be used in clinical 
practice in developed and developing world settings. Prior studies in coinfected patients have 
demonstrated that the baseline stage of hepatic fibrosis is strongly associated with ESLD [3, 19]. 
A separate analysis among coinfected women showed that FIB-4 was associated with all-cause 
mortality [34]. Among HIV-infected patients, baseline FIB-4 is associated with hepatocellular 
carcinoma risk [35]. In addition, FIB-4 uses a limited set of variables that are routinely and 
inexpensively measured in the outpatient setting, making this a useful option for resource-limited 
settings and practices where other non-invasive modalities of liver fibrosis assessment (e.g., 
transient elastography) might not be available. 
Race is also credible as a predictor of ESLD. Recent studies in coinfected patients reveal 
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that persons of non-black race have a higher risk of hepatic decompensation [3] and liver-related 
death [36]. A recent cohort study among 149,407 chronic HCV patients showed that blacks had 
lower rates of cirrhosis and hepatocellular carcinoma than non-Hispanic whites, even after 
adjustment for HCV genotype, HCV treatment, diabetes, and BMI [37]. Non-black HCV-
infected patients have been reported to have stronger HCV-specific immunity than blacks [38], 
which could result in increased immune-mediated hepatic inflammation and accelerated liver 
fibrosis progression. Recent analyses in HCV-monoinfected and HIV/HCV-coinfected patients 
suggest that interleukin-28B CC genotype, which is common in non-blacks, is associated with 
increased hepatic inflammation and worse hepatic outcomes than those with CT or TT genotypes 
[39, 40]. Differences in the distribution of other genetic and non-genetic factors may also explain 
the disparity in ESLD risk between blacks and non-blacks. In future analyses, such factors may 
prove to be better indicators of ESLD risk than race. 
This study has several potential limitations. First, we might have missed hepatic 
decompensation events and underestimated ESLD risk, since our decompensation definition did 
not include hepatic encephalopathy and because some patients did not have a confirmed cause of 
death. However, the incidence of ESLD among HIV/HCV patients in this study (8.8%) was 
similar to that reported in other cohort studies of coinfected patients [5, 19]. Further, we 
previously evaluated the incidence rate of decompensation within VACS, U.S. Medicare, and 
U.S. Medicaid data using the validated ICD-9 definition (to capture outcomes occurring at non-
VA hospitals that did not result in transfer to a VA facility). The incidence rate of 
decompensated cirrhosis was almost identical to that within the VACS alone, suggesting that few 
ESLD events were missed [3]. Second, our sample included mostly male U.S. veterans, and 
results may not be generalizable to women or to non-veteran populations. Future analyses should 
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evaluate the ability of FIB-4 and race to predict ESLD among coinfected women and non-
veterans. Third, differences by race in receiving HCV treatment (and being censored) should not 
affect our results because we stratified our analysis by race. Fourth, external validation of the 
prognostic model to predict ESLD in other coinfected populations is essential to ensure 
reproducibility of our findings across varied settings. Finally, although we considered many 
potential predictors during model development, data on liver stiffness measurement (using 
transient elastography) and genetic markers, such as interleukin 28B genotype  and interferon 
lambda-4 deltaG genotype [40, 41], were not assessed. Future models evaluating ESLD risk in 
coinfected patients could determine whether these factors improve accuracy and utility. 
However, FIB-4 and race have the advantage of being simple predictors. Further, since our final 
model included two categorical predictors, a simple Kaplan-Meier plot allows users to estimate 
risk easily for any given time frame. 
In summary, FIB-4 and race can be used to quantify the risk of ESLD among HIV/HCV-
coinfected patients on ART. Such information could prompt coinfected patients to reduce their 
risk factors for liver disease progression and aid HCV treatment decisions for both clinicians and 
patients. Future studies should evaluate the classification performance of FIB-4 and race in other 
coinfected populations, compare the performance of FIB-4 using the established cut-off points 
versus alternative thresholds, and determine if its use improves outcomes.
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Table 1. Baseline characteristics of the HIV/hepatitis C virus (HCV)-coinfected patients 
included in the study sample, overall and by end-stage liver disease status. 
 
Characteristic 
 
 Overall 
(n=6,016) 
End-Stage Liver 
Disease 
(n=532) 
No End-Stage 
Liver Disease 
(n=5,484) 
P-Value 
Median age (years, IQR) 48 (44-53) 49 (45-53) 48 (44-52) 0.061 
Male sex 5,929 (98.6) 532 (100.0) 5,397 (98.4) 0.003 
Race/ethnicity    <0.001 
Black 3,794 (63.1) 264 (49.6) 3,530 (64.4)  
Caucasian 1,474 (24.5) 164 (30.8) 1,310 (23.9)  
Hispanic 576 (9.6) 89 (16.7) 487 (8.9)  
Other/Unknown 172 (2.9) 15 (2.8) 157 (2.9)  
Body mass index    0.64 
<18.5 kg/m2 179 (3.0) 13 (2.4) 166 (3.0)  
18.5-24.9 kg/m2 3,045 (50.6) 259 (48.7) 2,786 (50.8)  
25-29.9 kg/m2 1,969 (32.7) 188 (35.3) 1,781 (32.5)  
30 kg/m2 661 (11.0) 56 (10.5) 605 (11.0)  
Missing weight and/or height 162 (2.7) 16 (3.0) 146 (2.7)  
Diabetes mellitus 483 (8.0) 47 (8.8) 436 (8.0) 0.47 
History of alcohol dependence/abuse 1,506 (25.0) 132 (24.8) 1,374 (25.1) 0.90 
HCV genotype    0.18 
1 or 4 3,553 (59.1) 306 (57.5) 3,247 (59.2)  
2 or 3 456 (7.6) 31 (5.8) 425 (7.7)  
Other 14 (0.2) 2 (0.4) 12 (0.2)  
No result available 1,993 (33.1) 193 (36.3) 1,800 (32.8)  
HCV RNA*    0.005 
≥400,000 IU/mL and/or ≥1,000,000 copies/mL 4,514 (75.0) 371 (69.7) 4,143 (75.5)  
<400,000 IU/mL and/or <1,000,000 copies/mL 647 (10.8) 62 (11.7) 585 (10.7)  
Qualitative HCV RNA result only 855 (14.2) 99 (18.6) 756 (13.8)  
Hepatitis B surface antigen    0.031 
Positive 263 (4.4) 33 (6.2) 230 (4.2)  
Negative 5,268 (87.6) 466 (87.6) 4,802 (87.6)  
No result available at baseline 485 (8.1) 33 (6.2) 452 (8.2)  
Median HIV RNA (copies/mL, IQR) 400 (75-4,870) 400 (179-3,726) 400 (75-4,905) 0.080 
HIV RNA    0.66 
>400 copies/mL 2,534 (42.1) 233 (43.8) 2,301 (42.0)  
≤400 copies/mL 3,245 (54.0) 277 (52.1) 2,968 (54.1)  
No result available at baseline 237 (3.9) 22 (4.1) 215 (3.9)  
Median CD4 cell count (cells/mm3, IQR) 320 (180-491) 294 (159-484) 322 (182-492) 0.043 
CD4 cell count    0.23 
500 cells/mm3 1,377 (22.9) 113 (21.2) 1,264 (23.0)  
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350-499 cells/mm3 1,156 (19.2) 94 (17.7) 1,062 (19.4)  
200-349 cells/mm3 1,544 (25.7) 135 (25.4) 1,409 (25.7)  
<200 cells/mm3 1,629 (27.1) 166 (31.2) 1,463 (26.7)  
No result available at baseline 310 (5.2) 24 (4.5) 286 (5.2)  
Hemoglobin    0.29 
<10 g/dL 161 (2.7) 18 (3.4) 143 (2.6)  
≥10 g/dL 5,820 (96.7) 509 (95.7) 5,311 (96.8)  
No result available at baseline 35 (0.6) 5 (0.9) 30 (0.5)  
APRI    <0.001 
<1.0 4,095 (68.1) 209 (39.3) 3,886 (70.9)  
1.0-2.0 1,003 (16.7) 153 (28.8) 850 (15.5)  
>2.0 591 (9.8) 142 (26.7) 449 (8.2)  
No result available at baseline 327 (5.4) 28 (5.3) 299 (5.5)  
FIB-4    <0.001 
<1.45 2,160 (35.9) 92 (17.3) 2,068 (37.7)  
1.45-3.25 2,561 (42.6) 205 (38.5) 2,356 (43.0)  
>3.25 968 (16.1) 207 (38.9) 761 (13.9)  
No result available at baseline 327 (5.4) 28 (5.3) 299 (5.5)  
Data are presented as number (%) unless otherwise specified.  
Abbreviations: HCV=hepatitis C virus; HIV=human immunodeficiency virus; IQR=interquartile range 
* Based on highest baseline HCV RNA result. 
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Table 2. Candidate prediction models for end-stage liver disease among 6,016 antiretroviral-
treated HIV/hepatitis C virus-coinfected patients. C-statistics for the base prognostic models 
consisting of FIB-4 (categorized as: <1.45; 1.45-3.25; >3.25) and APRI (categorized as: <1.0; 
1.0-2.0; >2.0) alone are presented in the top row. C-statistics for alternative prognostic models 
comprising FIB-4 or APRI plus select combinations of the other predictors are presented in 
subsequent rows below. Models with FIB-4 did not include age because age is a component of 
FIB-4. 
 
 
Prediction Model 
C-Statistic 
FIB-4-Based Model APRI-Based Model 
No additional predictors included (FIB-4 or APRI alone) 0.70 0.71 
Alcohol included 0. 71 0. 72 
Age included -† 0.73 
Race included 0.73 0.72 
Age + race included -† 0.74 
Race + diabetes + hepatitis B + anemia included 0.74 0.74 
Age + race + diabetes + hepatitis B + anemia included -† 0.75 
All predictors included*  0.74† 0.75 
Abbreviations: APRI=Aspartate aminotransferase (AST)-to-platelet ratio index 
* Covariates included age (for APRI-based model only), body mass index, anemia (hemoglobin <10 g/dL), 
CD4 cell count <200 cells/mm3, HIV RNA >400 copies/mL, history of alcohol dependence/abuse, diabetes 
mellitus, hepatitis B coinfection, and non-black race. FIB-4, APRI, hemoglobin, CD4 cell count, and HIV 
RNA level were also evaluated as continuous variables. 
† C-statistic was not evaluated within the FIB-4-based models because age is a component of FIB-4. 
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Figure 1. Selection of Veterans Aging Cohort Study (VACS) HIV/hepatitis C virus (HCV)-
coinfected patients for inclusion in the study. 
 
Abbreviations: ART=antiretroviral therapy; HIV=human immunodeficiency virus; HCV=hepatitis C virus; 
VACS=Veterans Aging Cohort Study 
3,598 Excluded: 
528 <12 months of follow-up 
122 Had end-stage liver disease prior to follow-up 
62 Received HCV therapy prior to follow-up 
1,180 Had an undetectable HCV RNA level 
1,706 Had missing HCV RNA level 
 
 6,016 
HIV/Chronic HCV Patients  
on ART 
 
9,614 
HCV Antibody-Positive/HIV-Infected 
Patients Dispensed ART 
 
14,832 
HCV Antibody-Positive/HIV-Infected 
Patients in the VACS (1997-2010) 
 
5,218 Excluded: Not dispensed ART 
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Figure 2. Risk of end-stage liver disease among antiretroviral-treated non-black (Panel A) and black (Pabel B) HIV/hepatitis C virus-
coinfected patients, by FIB-4 score.  
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